Retinitis Pigmentosa (Retinitis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Retinitis Pigmentosa (Retinitis) Pipeline Drugs Market Report Overview
Retinitis Pigmentosa (RP) refers to a group of diseases that cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance, and x-linked inheritance.
The Retinitis Pigmentosa pipeline drugs market research report provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Retinitis Pigmentosa and features dormant and discontinued projects.
Retinitis Pigmentosa Pipeline Drugs Market Segmentation by Targets
The key targets in the Retinitis Pigmentosa pipeline drugs market are Rhodopsin, Usherin, X Linked Retinitis Pigmentosa GTPase Regulator, Nucleoredoxin Like Protein 1, and others. Rhodopsin has the highest number of products in development in the Retinitis Pigmentosa pipeline drugs market.
Retinitis Pigmentosa Pipeline Drugs Market Analysis by Targets
For more target insights into the Retinitis Pigmentosa pipeline drugs market, download a free report sample
Retinitis Pigmentosa Pipeline Drugs Market Segmentation by Mechanisms of Action
The key mechanisms of action in the Retinitis Pigmentosa pipeline drugs market are Usherin Activator, Rhodopsin Activator, X Linked Retinitis Pigmentosa GTPase Regulator Activator, Nucleoredoxin Like Protein 1 Activator, and others. Usherin Activator leads the Retinitis Pigmentosa pipeline drugs market in terms of MoA.
Retinitis Pigmentosa Pipeline Drugs Market Analysis by Mechanisms of Action
For more MoA insights into the Retinitis Pigmentosa pipeline drugs market, download a free report sample
Retinitis Pigmentosa Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Retinitis Pigmentosa pipeline drugs market are intravitreal, intraocular, parenteral, ophthalmic, and others. The intravitreal RoA has the highest number of Retinitis Pigmentosa drugs in development in 2022.
Retinitis Pigmentosa Pipeline Drugs Market Analysis by Routes of Administration
For more RoA insights into the Retinitis Pigmentosa pipeline drugs market, download a free report sample
Retinitis Pigmentosa Pipeline Drugs Market Segmentation by Molecule Types
The key molecule types in the Retinitis Pigmentosa pipeline drugs market are gene therapy, small molecule, cell therapy, antisense oligonucleotide, and others. Gene therapy leads the Retinitis Pigmentosa pipeline drugs market in terms of molecule type.
Retinitis Pigmentosa Pipeline Drugs Market Analysis by Molecule Types
For more molecule type insights into the Retinitis Pigmentosa drugs market, download a free report sample
Retinitis Pigmentosa Pipeline Drugs Market - Competitive Landscape
Some of the leading companies in the Retinitis Pigmentosa pipeline drugs market are SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, and 4D Molecular Therapeutics Inc. SparingVision SAS has the largest number of Retinitis Pigmentosa drugs in development in 2022.
Retinitis Pigmentosa Pipeline Drugs Market Analysis by Companies
To know more about the leading Retinitis Pigmentosa pipeline drugs market players, download a free report sample
Retinitis Pigmentosa Pipeline Products Market Overview
| Key Targets | Rhodopsin, Usherin, X Linked Retinitis Pigmentosa GTPase Regulator, Nucleoredoxin Like Protein 1, and Others |
| Key Mechanisms of Action | Usherin Activator, Rhodopsin Activator, X Linked Retinitis Pigmentosa GTPase Regulator Activator, Nucleoredoxin Like Protein 1 Activator, and Others |
| Key Routes of Administration | Intravitreal, Intraocular, Parenteral, Ophthalmic, and Others |
| Key Molecule Type | Gene Therapy, Small Molecule, Cell Therapy, Antisense Oligonucleotide, and Others |
| Leading Companies | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics Inc, and Others |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa.
- The pipeline guide reviews pipeline therapeutics for Retinitis Pigmentosa by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Retinitis Pigmentosa therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Retinitis Pigmentosa therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Retinitis Pigmentosa
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Retinitis Pigmentosa.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the Retinitis Pigmentosa pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
Key Players
Table of Contents
List of Tables
List of Figures
Frequently Asked Questions
The key targets in the Retinitis Pigmentosa pipeline drugs market are Rhodopsin, Usherin, X Linked Retinitis Pigmentosa GTPase Regulator, Nucleoredoxin Like Protein 1, and others.
The key MoA in the Retinitis Pigmentosa pipeline drugs market are Usherin Activator, Rhodopsin Activator, X Linked Retinitis Pigmentosa GTPase Regulator Activator, Nucleoredoxin Like Protein 1 Activator, and others.
The key RoA in the Retinitis Pigmentosa pipeline drugs market are intravitreal, intraocular, parenteral, ophthalmic, and others.
The key molecule types in the Retinitis Pigmentosa pipeline drugs market are gene therapy, small molecule, cell therapy, antisense oligonucleotide, and others.
Some of the leading companies in the Retinitis Pigmentosa pipeline drugs market are SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, and 4D Molecular Therapeutics Inc.
Get in touch to find out about our multi-purchase discounts
reportstore@globaldata.com
Tel +44 (0) 20 7947 2960
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
Testimonial
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Related reports
View more Ophthalmology reports